Home » Stocks » RMTI

Rockwell Medical, Inc. (RMTI)

Stock Price: $0.933 USD 0.055 (6.24%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $0.902 -0.031 (-3.31%) May 7, 7:31 PM
Market Cap 85.01M
Revenue (ttm) 62.20M
Net Income (ttm) -30.89M
Shares Out 75.62M
EPS (ttm) -0.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $0.933
Previous Close $0.878
Change ($) 0.055
Change (%) 6.24%
Day's Open 0.879
Day's Range 0.879 - 0.938
Day's Volume 897,086
52-Week Range 0.830 - 2.470

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Rockwell Medical (RMTI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

1 week ago - Zacks Investment Research

WIXOM, Mich., April 22, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and i...

2 weeks ago - GlobeNewsWire

Rockwell Medical (RMTI) delivered earnings and revenue surprises of -12.50% and -5.34%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of Rockwell Medical (NASDAQ:RMTI) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 18.18% year over year to ($0.09), which mis...

1 month ago - Benzinga

On Wednesday, March 31, Rockwell Medical (NASDAQ:RMTI) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

1 month ago - Benzinga

Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Investors need to pay close attention to Rockwell Medical (RMTI) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

WIXOM, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and im...

2 months ago - GlobeNewsWire

>82,000 patients receiving hemodialysis annually >82,000 patients receiving hemodialysis annually

3 months ago - GlobeNewsWire

Rockwell Medical (RMTI) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

3 months ago - Zacks Investment Research

China is a sizable and growing market, with more than 600,000 patients receiving hemodialysis annually China is a sizable and growing market, with more than 600,000 patients receiving hemodialysis annually

3 months ago - GlobeNewsWire

WIXOM, Mich., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron d...

4 months ago - GlobeNewsWire

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Rockwell Medical (RMTI) delivered earnings and revenue surprises of -42.86% and -12.18%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q2 2020 Results - Quick Version Earnings Call Transcript

5 months ago - Seeking Alpha

Shares of Rockwell Medical (NASDAQ:RMTI) fell 2.17% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 16.67% over the past year to ($0.10), which w...

5 months ago - Benzinga

- Ended the quarter with $67.3 million in cash, cash equivalents and investments-

5 months ago - GlobeNewsWire

Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

WIXOM, Mich., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron d...

6 months ago - GlobeNewsWire

WIXOM, Mich., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron d...

6 months ago - GlobeNewsWire

-New indications for FPC platform provide significant growth opportunity-

7 months ago - GlobeNewsWire

WIXOM, Mich., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iro...

7 months ago - GlobeNewsWire

Rockwell Medical (RMTI) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

WIXOM, Mich., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iro...

7 months ago - GlobeNewsWire

Sizable and growing market opportunity with over 78,000 patients receiving hemodialysis annually Sizable and growing market opportunity with over 78,000 patients receiving hemodialysis annually

7 months ago - GlobeNewsWire

WIXOM, Mich., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iro...

7 months ago - GlobeNewsWire

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 23.08% and 0.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

-Q2 2020 revenue of $15.9 million-

8 months ago - GlobeNewsWire

WIXOM, Mich., June 10, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and...

10 months ago - GlobeNewsWire

WIXOM, Mich., May 26, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and ...

11 months ago - GlobeNewsWire

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 0.00% and 0.96%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

There could be a reason penny stocks trade for under $5, but the returns can be monstrous if there's even minor share price appreciation.

Other stocks mentioned: EVRI, GERN, MNLO, ORBC, PLUG, SELB
1 year ago - InvestorPlace

WIXOM, Mich., March 31, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to transforming anemia management and...

1 year ago - GlobeNewsWire

– Enhances Triferic platform by providing patients with greater access to Rockwell Medical’s innovative therapeutic by expanding administration options for clinicians –

1 year ago - GlobeNewsWire

WIXOM, Mich., March 20, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and...

1 year ago - GlobeNewsWire

First $22.5 million tranche funded at closing First $22.5 million tranche funded at closing

1 year ago - GlobeNewsWire

Rockwell Medical, Inc. (RMTI) CEO Stuart Paul on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 8.33% and -6.47%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

WIXOM, Mich., March 11, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and...

1 year ago - GlobeNewsWire

No Stockholder Action Required at This Time No Stockholder Action Required at This Time

1 year ago - GlobeNewsWire

-- Continued progress for Triferic® portfolio ---- 77% increase in the number of clinics under contract -- WIXOM, Mich., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwe...

1 year ago - GlobeNewsWire

WIXOM, Mich., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and ...

1 year ago - GlobeNewsWire

WIXOM, Mich., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and ...

1 year ago - GlobeNewsWire

- Sizable and growing market opportunity with 120,000+ patients receiving hemodialysis annually – - Sizable and growing market opportunity with 120,000+ patients receiving hemodialysis annually –

1 year ago - GlobeNewsWire

WIXOM, Mich., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to transforming anemia management and ...

1 year ago - GlobeNewsWire

About RMTI

Rockwell Medical, Inc. operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jan 27, 1998
CEO
Russell Ellison
Employees
300
Stock Exchange
NASDAQ
Ticker Symbol
RMTI
Full Company Profile

Financial Performance

In 2020, RMTI's revenue was $62.20 million, an increase of 1.46% compared to the previous year's $61.30 million. Losses were -$30.89 million, -9.49% less than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for RMTI stock is "Buy." The 12-month stock price forecast is 5.25, which is an increase of 462.76% from the latest price.

Price Target
$5.25
(462.76% upside)
Analyst Consensus: Buy